Moving your CBRN Advanced Development Program Forward

​​​​The Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote:

 

 BARDA encourages the advanced research and development of medical countermeasures such as vaccines, therapeutics, antitoxins, and diagnostics, as well as innovative approaches to meet the threat of chemical, biological, radiological, and nuclear (CBRN) agents in support of the preparedness mission and priorities as articulated in the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats.

 

As part of its mission to advance innovation, BARDA meets with companies that have promising technologies which may help the Nation respond to a public health emergency, either naturally occurring or intentionally induced.   These meetings are intended to provide industry with an opportunity to present their products to BARDA, solicit feedback, and facilitate communication.

 

Although BARDA meets with companies throughout the development process, it is most interested in products that have a Technology Readiness Level (TRL) of 5 or greater.  You can request a meeting with BARDA through MedicalCountermeasures.gov.

 

Please keep in mind that MedicalCountermeasures.gov does not accept unsolicited proposals and that BARDA cannot meet with companies that are currently competing for a contract under an active solicitation issued in accordance with the Federal Acquisition Regulation (FAR 15.306).

 

On June 8, 2012, BARDA issued the BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures.  This rolling BAA is intended to encourage the advanced research and development of medical countermeasures and innovative approaches to meet the threats posed by CBRN agents.  This BAA solicits proposals that focus on one or more of the following areas of interest:

 

Please keep in mind that a submission in response to this BAA constitutes competition for a contract under an active solicitation issued in accordance with the Federal Acquisition Regulation (FAR 15.306).  As such, companies cannot meet with BARDA personnel regarding products related to the submission until review and disposition of the white paper or full proposal.  This includes meetings that are requested through MedicalCountermeasures.gov.  However, if you would like to discuss a different concept or idea that you believe fits under the CBRN long-range BAA, you may request a meeting with BARDA to discuss this technology.